Mood Disorders

Evaluation of Mania and Hypomania in Late-Phase Clinical Trials of Lumateperone in the Treatment of Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder

This analysis evaluated mania and hypomania across 2 pooled, 6-week, placebo-controlled monotherapy studies; a 6-month open-label extension (OLE) monotherapy study; and a 6-week, placebo-...

Tobie Escher , PhD;

10/26/2023

Efficacy of Lumateperone in Pooled Short-Term Late-Phase Clinical Trials for the Treatment of Major Depressive Episodes Associated With Bipolar II Disorder

This post hoc, pooled analysis of 3 short-term, placebo-controlled studies evaluated the efficacy of once-daily lumateperone 42mg monotherapy and adjunctive therapy in patients experienci...

William Rowe , MSN, RN, ACNP, BC;

10/26/2023

Equivalent Antidepressant Outcomes with Esketamine in TMS Non-Responders

Both Transcranial Magnetic Stimulation (TMS) and Esketamine are FDA approved therapies for patients with Major Depressive Disorder who have failed at least one conventional antidepressant...

Tobias F. Marton , MD, PhD;

10/26/2023

Esketamine Nasal Spray Improves Functioning in Patients with Treatment Resistant Depression: Results from ESCAPE‑TRD

This analysis evaluated changes in functioning and productivity in patients with treatment resistant depression who received either esketamine nasal spray or quetiapine extended release, ...

Hannah Bowrey , PhD;

10/26/2023

EEG Individual Alpha Frequencies May Improve Depression Symptoms in TMS Treatment

69 patients were grouped based on their baseline individual alpha frequency (IAF): 8, 9, 10, or 11 Hz. We show the percentage of patients in each group that reported a decrease, increase,...

Rachel Lian , BS;

10/26/2023

Effect of Adjunctive Cariprazine on Symptoms of Anhedonia in Patients with Major Depressive Disorder

Results from this post-hoc analysis suggest adjunctive cariprazine treatment may be effective for improving symptoms of anhedonia in patients with major depressive disorder.

Majid Kerolous , PharmD, MPH;

10/26/2023

Effectiveness of Vortioxetine in Patients With Major Depressive Disorder and Early-Stage Dementia: The MEMORY Study

The MEMORY study demonstrates the effectiveness of vortioxetine in clinically significantly improving depressive symptoms, cognitive performance, daily functioning, and HRQoL, as well as ...

Michael Adair , MBChB;

10/26/2023

Effects of Adjunctive Brexpiprazole on Patient Life Engagement in Major Depressive Disorder Analyzed by Baseline Clinical Characteristics: Post Hoc analysis of a Phase 4, Open-Label Study

This post hoc analysis of a Phase 4, open-label, 8-week study evaluated if baseline clinical characteristics may influence the effect of adjunctive brexpiprazole on patient life engagemen...

Francois Therrien , PharmD;

10/26/2023

Cariprazine as an Adjunctive Treatment for Major Depressive Disorder: Assessment of Benefit and Risk Using Number Needed to Treat and Number Needed to Harm

The benefit-risk profile of cariprazine is favorable for major depressive disorder adjunctive treatment.

Majid Kerolous , PharmD, MPH;

10/26/2023

Changes in Metabolic Parameters Associated With Lumateperone in Late-Phase Clinical Trials for the Treatment of Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder

This analysis of 2 pooled, 6-week, placebo-controlled monotherapy studies; a 6-month open-label extension (OLE) monotherapy study; and a 6-week, placebo-controlled adjunctive study evalua...

Jazmin Acosta , PhD;

10/26/2023